Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system - Poll - MDSpire

Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system

  • By

  • Jiongrui Cao

  • Li Peng

  • Jin Yang

  • Gang Yin

  • Ping Ke

  • Jifa Zhang

  • Min Su

  • Yun Gao

  • Yuehui Zhang

  • June 17, 2026

  • 0 min

Share

Original Source(s)

Severe renal and pancreatic toxicities associated with ipilimumab and nivolumab combination therapy in non-small cell lung cancer: a pharmacovigilance analysis of the FDA adverse event reporting system

  • by Jiongrui Cao, Li Peng, Jin Yang, Gang Yin, Ping Ke, Jifa Zhang, Min Su, Yun Gao, Yuehui Zhang

  • June 17, 2026

Related Content

Expert consensus from the Chinese medical association on pharmaceutical management of combined cardio-oncology physician-pharmacist clinics

Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis

Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis